SCHEMBL23869346

SCHEMBL23869346

N#Cc1cccc(-c2cc(-n3c4ccccc4c4ccccc43)ncc2-n2c3ccccc3c3ccccc32)c1C#N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
HIF1A Q16665 1/20 0.37
PTGER4 P35408 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
DUSP3 P51452 1/20 0.32
EGFR P00533 1/20 0.32
SRC P12931 1/20 0.32
IMPDH2 P12268 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
NCOA1 Q15788 1/20 0.31
NCOA3 Q9Y6Q9 1/20 0.31
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31037700 0.94 SMN1; SMN2 (0.33) SMN1; SMN2HIF1APTGER4CNR1CNR2
SCHEMBL23855824 0.94 SMN1; SMN2 (0.33) SMN1; SMN2HIF1APTGER4CNR1CNR2
SCHEMBL23856007 0.94 SMN1; SMN2 (0.33) SMN1; SMN2HIF1APTGER4CNR1CNR2
SCHEMBL23868875 0.93 PTGDR2 (0.36) SMN1; SMN2HIF1APTGER4CNR1CNR2
SCHEMBL23869353 0.92 SMN1; SMN2 (0.39) SMN1; SMN2HIF1AALDH1A1CYP1A2CYP3A4
SCHEMBL23869352 0.91 GABRA1 (0.35) SMN1; SMN2HIF1APTGER4GABRA1GABRG2
SCHEMBL23855961 0.90 NR3C1 (0.34) SMN1; SMN2HIF1AALDH1A1CYP1A2CYP3A4
SCHEMBL23869023 0.90 RORA (0.32) SMN1; SMN2HIF1APTGER4EGFRALDH1A1
SCHEMBL23869366 0.88 SMN1; SMN2 (0.41) SMN1; SMN2HIF1AALDH1A1KDM4ECYP1A2
SCHEMBL23868874 0.87 PTGDR2 (0.36) SMN1; SMN2HIF1ACNR1CNR2IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029116-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2024-07-02 US disclosed
US-12029116-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2024-07-02 US disclosed
US-20210305517-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES KYULUX, INC. (JP) 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029116-B2 Composition of matter for use in organic light-emitting diodes OPRD1, DRD1, DRD3 SMN1; SMN2 3726/4885HIF1A 4659/4885PTGER4 334/4885
US-20210305517-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES OPRD1, DRD1, DRD3 SMN1; SMN2 3726/4885HIF1A 4659/4885PTGER4 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.